- Home
- ABLV vs ATNM Comparison
ABLV vs ATNM Comparison
Compare ABLV & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABLV
- ATNM
- Stock Information
- Founded
- ABLV 2015
- ATNM 2000
- Country
- ABLV China
- ATNM United States
- Employees
- ABLV N/A
- ATNM N/A
- Industry
- ABLV
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- ABLV
- ATNM Health Care
- Exchange
- ABLV Nasdaq
- ATNM Nasdaq
- Market Cap
- ABLV 51.4M
- ATNM 50.2M
- IPO Year
- ABLV N/A
- ATNM N/A
- Fundamental
- Price
- ABLV $0.90
- ATNM $1.67
- Analyst Decision
- ABLV
- ATNM Strong Buy
- Analyst Count
- ABLV 0
- ATNM 2
- Target Price
- ABLV N/A
- ATNM $4.50
- AVG Volume (30 Days)
- ABLV 31.1K
- ATNM 123.5K
- Earning Date
- ABLV 04-23-2025
- ATNM 11-13-2025
- Dividend Yield
- ABLV N/A
- ATNM N/A
- EPS Growth
- ABLV N/A
- ATNM N/A
- EPS
- ABLV N/A
- ATNM N/A
- Revenue
- ABLV $128,932,647.00
- ATNM N/A
- Revenue This Year
- ABLV N/A
- ATNM N/A
- Revenue Next Year
- ABLV N/A
- ATNM N/A
- P/E Ratio
- ABLV N/A
- ATNM N/A
- Revenue Growth
- ABLV N/A
- ATNM N/A
- 52 Week Low
- ABLV $0.55
- ATNM $1.03
- 52 Week High
- ABLV $1.77
- ATNM $2.41
- Technical
- Relative Strength Index (RSI)
- ABLV 47.81
- ATNM 50.97
- Support Level
- ABLV $0.91
- ATNM $1.61
- Resistance Level
- ABLV $1.00
- ATNM $1.70
- Average True Range (ATR)
- ABLV 0.14
- ATNM 0.07
- MACD
- ABLV 0.00
- ATNM -0.01
- Stochastic Oscillator
- ABLV 11.50
- ATNM 51.79
About ABLV Able View Global Inc.
Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.